The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer.
BACKGROUND The efficacy of neoadjuvant immunochemotherapy (NIC) in limited-stage small-cell lung cancer (LS-SCLC) remains undefined. This study aimed to evaluate the pathological and survival outcomes of NIC versus neoadjuvant chemotherapy (NC) and to compare NIC with upfront surgery in a real-world setting. MATERIAL...